Product Images Ondansetron

NDC 0641-6078-01 is a medication called Ondansetron available in injection form by Westward. The other text appears to be non-readable characters.*

This is a table that shows the percentage of adult patients who experienced certain adverse reactions after being treated with either Ondansetron Injection or Metoclopramide Placebo. The reactions measured were Diarrhea, Headache, and Fever. The number of patients studied is also provided for each treatment group.*

This text shows the adverse reactions of Ondansetron Injection compared to a Placebo for 4 mg Intravenous on a sample group of 547. The reactions mentioned are headache, drowsiness/sedation, injection site reaction, fever, cold sensation, pruritus, and paresthesia. The percentage of people who experienced these reactions are also provided for both Ondansetron Injection and Placebo.*

This is a table showing the peak plasma concentration, mean elimination half-life, and plasma concentration in various age groups. The age groups are divided into 19-40 years, 61-74 years, and an unspecified age group with 275 participants. The table also displays the number of participants in each age group. The values displayed are the plasma concentration in ng/mL, the half-life in hours, and the plasma concentration in L/h/kg.*

This appears to be a table showing the volume of distribution for pediatric cancer patients and population pharmacokinetic (PK) patients of different age groups. It includes data such as the number of subjects in each group, geometric mean, and average mean. The units are given in liters per hour per kilogram (L/h/kg) or liters per kilogram per hour (L/kg/h) for pediatric cancer patients and L/kg for population PK patients. The age range for pediatric cancer patients is 4 to 18 years and for population PK patients it is 1 month to 48 months.*

This is a description of a study on pharmacokinetics in pediatric surgery patients. The study includes three age groups: 1-4 months, 5-24 months, and 3-12 years. The number of patients (N) in each group is provided. The results of the study report the geometric mean for the clearance (CL), volume of distribution (Vdss), and half-life (t1/2) for each group. The mean t1/2 for all groups is 2.9 hours, except for the 1-4 month group with a mean t1/2 of 6.7 hours.*

This is a description of the results of a clinical trial comparing two treatments for nausea and vomiting. The data show the number of patients, treatment response, and various outcomes such as emetic episodes, time to first emetic episode, nausea scores, and global satisfaction with control of nausea and vomiting. The trial used two treatments: Ondansetron Injection and Placebo. The data shows that Ondansetron Injection was more effective than Placebo in reducing emetic episodes and improving other outcomes. P-values are reported for each outcome, indicating the level of statistical significance.*

This is a statistical table containing data related to the efficacy of Ondansetron Injection and Metoclopramide in treating nausea and vomiting in patients. The data includes the number of patients who responded to treatment based on the severity of emetic episodes, median number and time of emetic episodes, and global satisfaction with control of symptoms. The table also provides information on the occurrence of acute dystonic reactions and akathisia in patients. The data shows a comparison between the two treatments and the associated p-values.*

This is a comparative study between Ondansetron Injection and Placebo for controlling nausea and vomiting in patients undergoing chemotherapy. The study includes the number of patients, treatment response, median number of emetic episodes, median time to first emetic episode, median nausea scores, and global satisfaction with control of nausea and vomiting. The data shows that Ondansetron Injection is more effective in reducing emetic episodes (0 vs. 2), better control of nausea, and improved global satisfaction compared to Placebo. The P-value indicates that the difference between the two groups is statistically significant.*

This text seems to describe the results of two studies (Study 1 and Study 2) examining the number of emetic episodes and treatment response over a 24-hour postoperative period. Both studies looked at the number of patients who experienced 0, 1, and more than 1 emetic episode/rescued, as well as the number of patients who reported no nausea during this period. Study 2 specifically examined the effects of a medication called ondansetron (4mg intravenous) compared to a placebo. The text includes numerical data for the number of patients in each group and the percentage who experienced each type of outcome. A P value is also provided.*

This text presents results from three different studies measuring treatment response over 24 hours, with each study showing no emetic episodes. The studies also included assessments of nausea, with varying percentages of patients experiencing relief when treated with ondansetron compared to a placebo. P-values were also provided for the differences between ondansetron and placebo treatments.*

The text describes the results of two different studies in relation to the treatment response of patients to ondansetron, a drug used to prevent nausea and vomiting after surgery. The studies analyzed the number of emetic episodes experienced by the patients, their response to the medication 24 hours after taking it, and their median time to the first emetic episode. The text also includes the number of patients who reported nausea and the mean nausea score over a 24-hour period. The results are compared with those of a group of patients who were given a placebo.*

This is a table that shows the treatment response of ondansetron and placebo over 24 hours in terms of the number of patients and the percentage of them who had no emetic episodes. The number of patients who had no emetic episodes after taking ondansetron was 96 out of 180, which was higher than the number of patients who had no emetic episodes after taking placebo as only 29 out of 171 patients had a similar response. The difference was statistically significant (p-value <0.001). However, the table also indicates that the treatment failed in 47% of patients who took ondansetron.*

This text provides instructions for administering a medication, including recommended dosage and timing for different patient populations. The medication can be given to adults and pediatric patients over 12 years old to prevent nausea and vomiting before or after surgery. The recommended dose is 4 mg, which can be administered intravenously or intramuscularly. For pediatric patients, the dosage varies based on weight, but the medication is given intravenously in the same manner as for adults. It's important to infuse the medication over at least 30 seconds, preferably longer, to ensure proper administration.*

This text represents the distribution information for a company named HF Acquisition based in Mukilteo, WA 98275.*